The Story: A Skincare Founder Who Said No to Venture Capital, Twice, Then a Hundred Times
Jack Jia had a problem most founders would envy. By 2025, Musely, the direct-to-consumer telemedicine platform he co-founded in 2014, was growing at 50% year-over-year, had served over 1.2 million patients, and had been cash flow positive for years. Venture capitalists were lining up at the door. He kept turning them away.
The logic was simple and stubborn: after raising $20 million from DCM and other investors back in 2014, Jia had not taken a single dollar of equity capital since. He had watched peers in the DTC health space raise round after round, shrink their ownership to slivers, and hand governance to investors whose timelines rarely matched a founder’s vision. He wanted no part of it.
But Jia understood one uncomfortable truth about scaling a DTC brand. “When you become a billion-dollar revenue company, you need another billion in order to grow to the next billion,” he told TechCrunch. Customer acquisition in DTC is capital-intensive by design. The business had momentum; what it needed was fuel, without a match struck to the cap table.
The answer arrived from an unexpected direction. General Catalyst’s Customer Value Fund (CVF), a vehicle that operates entirely separately from its traditional venture equity strategy, approached Musely not with a term sheet for equity, but with something structurally different: a revenue-share agreement. No interest rate. No board seat. No dilution. Musely would receive capital and repay it, along with a fixed, capped percentage of the revenue generated from deploying that capital. In May 2026, Musely announced it had secured over $360 million through this structure, the largest non-dilutive financing of its kind in the DTC healthcare space. Jia’s ownership: untouched. His cap table: clean. His board: still his.
“When I mathematically modeled it, I found this absolutely compelling,” he said. [techcrunch.com]
The Decision: What Were the Real Alternatives?
To appreciate what Jia chose, you have to price what he declined. A traditional venture round at Musely’s scale and growth rate would almost certainly have come with a valuation negotiation, meaningful dilution, liquidation preferences, anti-dilution provisions, and at least one new board seat handed to an investor whose fund lifecycle might peak in five years. A bank line of credit, if available at this size, would carry interest rate costs and covenants. Neither fit.
CVF’s revenue-share structure threaded the needle. The capital cost was mathematically superior to equity dilution and more flexible than fixed-rate debt. Repayment was tied directly to the revenue generated by the funded activity, customer acquisition, meaning Musely wasn’t servicing a loan from core operations but from the incremental returns the capital itself was producing. The structure aligned incentives between funder and founder rather than pitting them against each other.
Musely’s story isn’t isolated. Austin-based collaboration analytics company Vyopta faced a similar fork in the road in 2020. Rather than accept dilutive venture debt, which typically requires a concurrent equity injection, Vyopta partnered with Vistara Growth for pure growth debt: a non-amortizing term loan underwritten against the business’s own fundamentals, not its investors’ willingness to write a new check. Over four years, Vyopta hit milestone after milestone without touching its cap table. When HP acquired the company in June 2024, the founders and investors collected a clean exit: no preference stack to navigate, no complex waterfall, no investor disputes. [vistaragrowth.com]
The Outcome: What the Numbers Actually Look Like
The contrast between dilutive and non-dilutive paths becomes starkest when you model the ownership math.
Consider Inkle, an all-in-one financial operations platform for VC-backed startups that used non-dilutive financing from Efficient Capital Labs instead of raising a Seed and Pre-Series A round. The result: the founding team retained approximately 90% of company equity and full board control, scaled to serve 500+ companies globally, and grew their engineering team by 50%, all without a single new investor at the table. [ecaplabs.com]
Or take Ken Hoppe, CEO of Modigi, a lean SaaS company operating inside the Salesforce ecosystem. With just six full-time employees, Modigi reached $1.7 million in ARR profitably. When Hoppe needed capital to hire his first salesperson and customer success manager, he turned to Founderpath’s revenue financing, $400,000 funded in under 72 hours, no collateral, no equity, no board seats. “It’s my own money and my co-founder’s money. Founderpath helped us keep control of the company while still getting the capital we needed to grow,” Hoppe said. The company retained 100% founder ownership and is now targeting $3–4 million in EBITDA within 24 months. [founderpath.com]
And the approach isn’t limited to SaaS or DTC. In May 2026, Mistral AI, Europe’s most prominent large language model company, raised $830 million in pure debt financing from a seven-bank consortium to fund a sovereign GPU cluster near Paris. With $400 million in ARR and a credible path to $1 billion, Mistral could access debt at a cost of capital almost certainly lower than the implied dilution of issuing new equity. Its founders, early backers, and strategic investors kept every percentage point they had earned. [udit.co]
The Lessons: A Framework for Founders Facing the Same Choice
These stories share a structure worth internalizing. Across Musely, Vyopta, Inkle, Modigi, and Mistral, several conditions made non-dilutive capital the superior choice:
1. Predictable, recurring revenue. Every deal above was underwritten against visible cash flows: ARR, MRR, patient acquisition economics, or enterprise SaaS contracts. Revenue-share agreements and growth debt require a lender to see repayment capacity. If your revenue is lumpy or early, this path is harder to access.
2. A founder who has priced their equity honestly. Jia didn’t just prefer to keep his equity; he had modeled exactly what giving it up would cost. Founders who take dilutive rounds without running that comparison are making an uninformed decision. The math almost always surprises them.
3. Capital deployed into measurable ROI activities. Customer acquisition, sales headcount, market expansion; these are activities where the return on capital can be estimated in advance. That predictability is what makes revenue-share structures and growth debt fundable. Raising equity for vague “runway” or exploratory R&D is a different use case.
4. Exit optionality protected by a clean cap table. Vyopta’s acquisition by HP was smoother precisely because there was no complex preference stack to negotiate through. Non-dilutive capital leaves future exit proceeds where they belong, with the people who built the business.
The emerging landscape of non-dilutive financing (revenue-share funds, growth debt, venture lending underwritten on fundamentals rather than investor relationships) is giving founders more paths than the traditional binary of equity or nothing. The founders who understand this early keep more of what they build. Those who default to equity because it feels familiar are paying a price they often don’t see until the wire hits on exit day.
Key Insights
- Revenue-share financing can cost less than equity. When modeled properly, as Musely’s Jack Jia did, a capped revenue-share repayment structure is frequently cheaper in dollar terms than issuing new equity at a negotiated valuation, particularly for fast-growing companies.
- Clean cap tables command cleaner exits. Vyopta’s acquisition by HP in 2024 demonstrated that companies with no complex preference stack are more attractive to acquirers and deliver higher net proceeds to founders and early shareholders.
- Non-dilutive capital now scales to institutional size. The era of revenue-based financing being limited to sub-$5M rounds is over. Musely’s $360M and Mistral’s $830M debt raise prove that the instrument scales with the company.
- Predictable revenue is the underwriting currency. Whether the structure is revenue-share, growth debt, or a bank consortium facility, recurring and visible cash flows are what unlock access: ARR, MRR, or contracted enterprise revenue are the assets that matter.
- Founder control is a compounding asset. Every board seat ceded and every dilutive round closed is a governance decision that compounds over time. Founders who preserve control through non-dilutive structures retain the ability to make long-term decisions without quarterly pressure from investors on finite fund timelines.
